Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have been assigned a consensus recommendation of “Buy” from the thirteen analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, ten have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $86.90.

JANX has been the topic of a number of recent analyst reports. Piper Sandler started coverage on Janux Therapeutics in a research report on Monday, August 18th. They set an “overweight” rating and a $42.00 target price on the stock. Raymond James Financial assumed coverage on Janux Therapeutics in a research note on Friday, July 11th. They issued an “outperform” rating and a $65.00 target price for the company.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of JANX. GF Fund Management CO. LTD. purchased a new stake in shares of Janux Therapeutics in the fourth quarter valued at $59,000. GAMMA Investing LLC raised its holdings in shares of Janux Therapeutics by 1,574.0% in the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company’s stock worth $45,000 after purchasing an additional 1,574 shares during the period. US Bancorp DE raised its holdings in shares of Janux Therapeutics by 2,402.9% in the 1st quarter. US Bancorp DE now owns 1,727 shares of the company’s stock worth $47,000 after purchasing an additional 1,658 shares during the period. FNY Investment Advisers LLC grew its stake in shares of Janux Therapeutics by 6,928.6% in the first quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company’s stock valued at $66,000 after buying an additional 2,425 shares in the last quarter. Finally, KBC Group NV acquired a new stake in shares of Janux Therapeutics in the first quarter valued at about $66,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Trading Up 0.8%

Shares of NASDAQ:JANX opened at $23.04 on Thursday. Janux Therapeutics has a twelve month low of $21.97 and a twelve month high of $71.71. The company’s 50 day moving average is $24.50 and its 200 day moving average is $26.93. The company has a market cap of $1.38 billion, a PE ratio of -12.80 and a beta of 2.84.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.07). Equities research analysts predict that Janux Therapeutics will post -1.38 earnings per share for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.